BioCentury
ARTICLE | Clinical News

Emend regulatory update

April 4, 2016 7:00 AM UTC

Japan approved a regulatory application from Ono for IV Proemend fosaprepitant meglumine to include treatment of chemotherapy-induced nausea and vomiting (CINV) in pediatric patients ages >=6 months. The injectable formulation of the selective neurokinin 1 (NK1) receptor antagonist is marketed to treat CINV in adults and pediatric patients ages >=12 resulting from antineoplastic agents. ...